BioCentury
ARTICLE | Clinical News

CCX872: Phase Ib started

May 4, 2015 7:00 AM UTC

ChemoCentryx began an open-label Phase Ib trial to evaluate 150 mg oral CCX872 twice daily plus FOLFIRINOX chemotherapy for >=12 weeks in up to 54 patients. ...